首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Novel GAA sequence variant c.1211 A > G reduces enzyme activity but not protein expression in infantile and adult onset Pompe disease
Authors:MI Nilsson  MA Kroos  AJ Reuser  E Hatcher  M Akhtar  ME McCready  MA Tarnopolsky
Institution:1. Department of Pediatrics, McMaster University Medical Centre, 1200 Main Street West, Hamilton, Ontario, Canada L8 3Z5;2. Department of Pathology and Molecular Medicine, McMaster University Medical Centre, 1200 Main Street West, Hamilton, Ontario, Canada L8 3Z5;3. Department of Clinical Genetics and Pediatrics, Erasmus MC University Medical Center, Rotterdam, Netherlands;4. Center for Lysosomal and Metabolic Disease, Erasmus MC University Medical Center, Rotterdam, Netherlands
Abstract:Pompe disease is a clinically and genetically heterogeneous autosomal recessive disorder caused by lysosomal acid α-glucosidase (GAA) deficiency. We report on two affected members of a non-consanguineous Caucasian family, including a classical infantile-onset patient with severe cardiomyopathy (IO) and his paternal grandmother with the adult-onset (AO) form. Two compound heterozygous sequence variants of the GAA gene were identified in each patient by mutation analyses (IO = c.1211A > G and c.1798C > T; AO = c.1211A > G and c.692 + 5G > T). For this study, the biochemical phenotype resulting from the missense mutation c.1211A > G in exon 8, which converts a highly conserved aspartate to glycine (p.Asp404Gly), was of specific interest because it had not been reported previously. Western blotting revealed a robust expression of all GAA isoforms in quadriceps muscle of both patients (fully CRIM positive), while enzymatic activity was 3.6% (IO) and 6.6% (AO) of normal controls. To further validate these findings, the c.1211A > G sequence variant was introduced in wild type GAA cDNA and over-expressed in HEK293T cells. Site-directed mutagenesis analyses confirmed that the mutation does not affect processing or expression of GAA protein, but rather impairs enzyme function. Similar results were reported for c.1798C > T (p.Arg600Cys), which further supports the biochemical phenotype observed in IO. The third mutation (c.692 + 5G > T, in intron 3) was predicted to affect normal splicing of the GAA mRNA, and qPCR indeed verified a 4-fold lower mRNA expression in AO. It is concluded that the novel sequence variant c.1211A > G results in full CRIM but significantly lower GAA activity, which in combination with c.1798C > T leads to infantile-onset Pompe disease. We surmise that the difference in disease severity between the two family members in this study is due to a milder effect of the intronic mutation c.692 + 5G > T (vs. c.1798C > T) on phenotype, partially preserving GAA activity and delaying onset in the proband (paternal grandmother).
Keywords:4-MU  4-methylumbelliferone  A  adenosine  AO  adult onset  Asp  aspartic acid  Arg  arginine  C  cytidine  cDNA  DNA complementary to RNA  CON  control(s)  CK  creatine kinase  CRIM  cross-reactive immunologic material  Cys  cysteine  ERT  enzyme replacement therapy  FEV  forced expiratory volume  FVC  forced vital capacity  G  guanosine  GAA  acid α-glucosidase (gene)  GAA  acid α-glucosidase (protein)  Gly  glycine  GSD II  glycogen storage disorder type II  HET  heterozygous  HRP  horseradish peroxidase  IO  infantile onset  IVS  intervening sequence  kDa  kilodalton(s)  NaAc  sodium acetate  PCR  polymerase chain reaction  RT  room temperature  T  thymidine  TRIS  tris-buffered saline  3&rsquo  UTR  three prime untranslated region  WB  western blotting
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号